Study of an experimental drug for CALR-mutant myeloproliferative neoplasms
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial is testing an experimental drug called DMR-001 for people with blood cancers like ET or myelofibrosis who have a specific genetic change known as a CALR mutation. The goal is to see if the drug is safe, tolerable, and helps treat the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with essential thrombocythemia (ET) or myelofibrosis (MF)
- You have a specific gene change called a CALR mutation (this is tested by your doctor)
- You are willing to have a bone marrow biopsy and aspiration as part of the study
- You have been free of any other cancer for at least 2 years
- You have not had a stem cell transplant or donor white blood cell infusion in the past
- You do not have active hepatitis B, hepatitis C, or HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
This Phase 2 trial tests whether elritercept, given alone or together with ruxolitinib, can improve symptoms and disease control in adults with myelofibrosis. It may help people who have anemia and either cannot tolerate, can’t get enough benefit from, or are already using ruxolitinib.
This trial tests a new drug, INCA033989, alone or with ruxolitinib for people with certain blood cancers called myeloproliferative neoplasms (MPNs). It may help those with a specific genetic change (CALR mutation) who have not had success with other treatments.
This study tests an experimental drug called JNJ-88549968 in people with certain blood cancers (essential thrombocythemia or myelofibrosis) that have a CALR gene mutation. It may offer a new treatment option for those who haven't responded well to other therapies.
This trial tests a new drug, INCA035784, for people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It may help if your MPN is called myelofibrosis (MF) or essential thrombocythemia (ET) and has a specific genetic change (CALR mutation), and you've already tried other treatments.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
Hear when a new Myeloproliferative Neoplasms (MPNs) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.